The SWOG-S1616 trial, involving anti-PD-1-resistant melanoma patients, demonstrated that combining ipilimumab and nivolumab (higher ORR compared to ipilimumab monotherapy, HR 0.63, indicating an improvement in PFS) [128]. This evidence concerns the gene PDCD1 and melanoma.